ALTSTATION.IO

Baxter International Inc. (BAX) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$21.50

Change

-1.26%

Market Cap

$11.05B

Avg Volume

8.5M

Company Overview

Baxter International Inc. provides a wide range of healthcare products focused primarily on medical instruments and supplies. Their portfolio includes sterile intravenous solutions, infusion systems, parenteral nutrition therapies, and surgical hemostat products. Customers include hospitals, nursing homes, rehabilitation centers, and home patients under physician supervision. Baxter sells its products through a direct sales force, independent distributors, and wholesalers, covering diverse healthcare settings globally.

Baxter is positioned as a market leader in the medical instruments and supplies sector. They face competition from companies like Medtronic and Becton Dickinson, which also offer critical healthcare solutions. Baxter’s edge lies in its diverse product offerings and solid relationships with healthcare providers. However, they face threats from rising competition and pricing pressures, especially for generic injectable pharmaceuticals.

Currently, Baxter is in a growth phase, with an emphasis on innovation and expanding its portfolio. The company has been actively pursuing strategic partnerships, such as its agreement with Celerity Pharmaceuticals to develop acute care generic injectables. Recent financial reports indicate a steady increase in revenue, suggesting a strong recovery from past challenges and setting the stage for future growth.

Key Financials

Market Cap

$11.05B

Revenue

$11.02B

EBITDA

$2.07B

Gross Margin

37.9%

Profit Margin

-3.1%

Revenue Growth

5.0%

Total Cash

$1.73B

Total Debt

$9.71B

Free Cash Flow

$2.62B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

N/A

Forward P/E

9.48

Beta

0.58

52-Week High

$37.74

52-Week Low

$17.40

EPS

$-0.70

50-Day Avg

$19.47

200-Day Avg

$24.27

Price/Book

1.53

Technical Analysis

Over the past 52 weeks, Baxter International Inc. (BAX) has shown a distinctly bearish trend, with a significant decline of 28.2%, dropping from approximately $30 to the current price of $21.50. Key support levels are evident around $21, where recent price action has shown some stabilization, while immediate resistance is identified at around $30, which had previously acted as a psychological barrier. The chart shows notable lower highs and lower lows, validating the descending trend line that runs through peaks since February, indicating ongoing selling pressure. Recently, there has been a slight recovery, with the price edging upward after hitting the $20.00 mark in December and January. Currently, at $21.50, the price sits near the lower end of its 52-week range, suggesting potential for a rebound but also highlighting a continued risk of further declines if support fails.

Recent News and Developments

Here are the latest news and developments for Baxter International Inc

(BAX) stock in the past week, from January 31, 2026, to February 7, 2026:

1. Baxter to Report Q4 2025 Earnings Next Week

Baxter International Inc. (BAX) is scheduled to release its fourth-quarter 2025 financial results before the market opens on Thursday, February 12, 2026. Analysts are anticipating the company to report earnings of $0.53 per share and revenue of approximately $2.8248 billion for the quarter. Investors will be closely watching this report for updates on the company’s performance and future guidance.

2. Ongoing Concerns Regarding Novum IQ Infusion Pump Shipment Hold

Investor concerns continue to surround Baxter’s infusion pump portfolio, specifically the ongoing shipment hold on the Novum IQ pump. This hold, tied to two deaths, was noted as a factor contributing to investor worries as of January 31, 2026, and is expected to extend into 2026, adding near-term pressure on the company. The delayed normalization of IV fluid volumes following Hurricane Helene has also continued to impact revenue.

Market Sentiment and Analyst Recommendations

Bull Case

Baxter trades at a massive discount to its 52-week high of $37.74, currently sitting 43% below that level. The 6.8% stake by FMR LLC signals institutional confidence in the turnaround story. Q4 earnings on February 12 will be the first real test of whether management can stabilize revenue growth after the Novum IQ pump hold and Hurricane Helene disruptions. The Dynamo Series smart stretcher launch represents a genuine product innovation entering the hospital workflow market in H1 2026, a potential new revenue stream in a fragmented medtech space. With $1.73B in cash against $9.71B debt, the balance sheet has breathing room for operations and potential M&A. At current levels, if the company can normalize IV fluid volumes and resolve the pump shipment hold by mid-2026, the $23-25 analyst target range becomes achievable within 12 months.

Bear Case

The 28.2% decline over 52 weeks reflects real operational problems, not just market sentiment. The Novum IQ infusion pump hold tied to two deaths is a serious liability issue that extends into 2026, directly impacting a core product line. Debt-to-cash ratio of 5.6x is problematic for a company facing near-term headwinds, limiting financial flexibility. Revenue growth of 5% is anemic for a healthcare company, especially one dealing with supply chain disruptions that should be temporary but clearly aren’t normalizing fast enough. The lack of a P/E ratio suggests the market isn’t confident in earnings power right now. With 15 analysts split between buy and hold ratings and targets ranging wildly from $15 to $42, there’s no consensus on where this stock actually belongs.

What to Watch

Q4 2025 earnings on February 12 are make-or-break: watch for guidance on when Novum IQ shipments resume and whether IV fluid volumes have stabilized post-Hurricane Helene. Specifically, look for revenue trends in the infusion and critical care segment, which should show sequential improvement if the worst is behind them. Track the Dynamo Series stretcher order pipeline and early adoption rates once deliveries begin in H1 2026, as this validates the innovation narrative. Monitor debt reduction progress and free cash flow generation over the next two quarters, since the 5.6x debt-to-cash ratio limits downside protection. If the stock breaks below $21 support, it signals the market sees further deterioration ahead. Conversely, a sustained move above $25 after earnings would suggest the pump hold concerns are pricing out and recovery is real.

Analyst Consensus

NONE

Based on 15 analyst opinions

Low Target

$15.00

Mean Target

$23.13

High Target

$42.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Instruments & Supplies

Employees

38,000

Earnings & Dividends

Next Earnings

Feb 12, 2026

EPS (Trailing)

$-0.70

Dividend Yield

239.0%

Payout Ratio

307.7%

Frequently Asked Questions

Is BAX a good stock to buy?

Baxter International Inc. (BAX) is trading at $21.50, well below its 52-week high of $37.74. With a forward P/E of 9.48 and a market cap of $11.05 billion, it may be undervalued compared to its peers. However, investors should consider the company’s financial stability and growth prospects before making a decision.

What is BAX’s price target?

Baxter does not currently have any analyst recommendations, but the average target price is $23.13. This suggests a potential upside of about 7.6% from the current price. Keep in mind, price targets can be optimistic and should be viewed critically.

Does BAX pay a dividend?

Yes, Baxter has a remarkably high dividend yield of 239.0%. Investors should note that such a high yield can often indicate financial distress or sustainability issues, typically warranting further investigation into the company’s financial health.

What is BAX’s P/E ratio?

Baxter’s P/E ratio is not available (N/A), suggesting it may not be generating positive earnings. However, the forward P/E of 9.48 indicates anticipated earnings growth. This combination may signal a turnaround in the future, but caution is advised.

What sector is Baxter in?

Baxter operates in the healthcare sector, specifically within the medical instruments and supplies industry. This sector can provide stability during market volatility, but investors should evaluate individual company performance against sector trends.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.